Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim - LARVOL DELTA

Heterogeneous treatment effects in biologic therapies for psoriasis: a causal forest analysis of the BADBIR registry (EADV 2025) - "Eligible participants were biologic naïve, received first-course monotherapy with either TNFi (adalimumab), IL12/23i (ustekinumab), IL17i (secukinumab, ixekizumab), or IL23i (guselkumab, risankizumab, tildrakizumab) with one year follow-up data. This causal forest analysis revealed distinct patterns of treatment effect heterogeneity across biologic classes in psoriasis based on patient characteristics. While IL23i demonstrated consistent superiority over TNFi, responses to IL17i and IL12/23i showed greater variation dependent on patient phenotypes. The identification of negative conditional treatment effects in certain subgroups warrants consideration for patient selection."

Heterogeneity • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

Comparative Durability of Biologics for Patients with Moderate-to-Severe Psoriasis Adjusted for Drug Switching Over Time: 24-Month Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO) (EADV 2025) - "Durability in the PSoHO study is based on rapid skin clearance and sustained therapeutic response, the primary treatment goals of many patients with PsO (1, 2). It has previously been demonstrated that patients who achieve PASI100 earlier experience more days under a DLQI score of 0 or 1, emphasizing the correlation between the time taken to achieve total skin clearance and patients' quality of life (3). A limitation of long-term observational studies is potential bias caused by treatment switching, which can be impacted by study length, higher skin involvement, treatment costs, and access, but also by comorbid PsA, which approximately one-third of pts with PsO also suffer from."

Clinical • HEOR • Dermatology • Immunology • Psoriasis

Real-world 52-week effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a prospective single-centre cohort (EADV 2025) - "In routine practice, risankizumab delivers rapid and durable disease control and quality-of-life gains through 52 weeks, with an excellent safety profile, in a representative plaque-psoriasis population."

Clinical • Real-world • Real-world evidence • Dermatology • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL23A

Understanding patient types prescribed oral advanced therapies or biologics for psoriasis: Results from a real-world survey in Germany (EADV 2025) - "Dermatologists also provided data for additional patients receiving either bimekizumab, risankizumab or deucravacitinib, for inclusion in treatment specific analysis...Patients receiving approved advanced treatments at the time of survey were grouped as: oral advanced treatments (OATs: apremilast or deucravacitinib) or biologics... Most patients prescribed OATs or biologics met accepted criteria of moderate-to-severe PsO including BSA ≥10% and special areas affected, while only about a quarter met the PASI minimum of 12 from clinical trials criteria. Patient-reported goals such as complete skin clearance and rapid onset of action were key drivers of treatment choice. Further research is needed to understand physicians' rationale regarding choice of systemic treatments, suitability to OATs or biologics and to assess whether clinical trial PASI criteria should be adapted to better reflect real-world patient profiles."

Clinical • Metastases • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

Time to Treatment Change in Patients Receiving Risankizumab vs Other Biologic Therapies Over 3 years: Interim Analysis of the VALUE Study (EADV 2025) - P | "In this interim analysis, pts receiving RZB were significantly less likely to require TSC than pts receiving OtherBios over 37 months. When TSCs were needed, pts receiving RZB had a significantly longer time to first TSC compared to pts receiving OtherBios. These results were mostly consistent in the bio-naive and bio-exp populations."

Clinical • Dermatology • Immunology • Psoriasis • IL23A

Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection (EADV 2025) - "This review emphasizes the clinical and molecular parallels between IBD and psoriasis, particularly their multifocal inflammatory nature and shared immunopathogenesis via the gut-skin-joint axis. While IL-17 antagonism is effective in psoriasis, it may exacerbate IBD, highlighting the complexity of shared treatment. Dysbiosis and T-cell imbalance further illustrate the diseases' interconnection."

Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pruritus • Psoriasis • Ulcerative Colitis • IL12B • IL23A • TNFAIP3

Transcriptomic identification of immune-related hubs as predictor biomarkers oftherapeutic response in Psoriatic Disease (EADV 2025) - "While biologics like adalimumab (anti-TNFα) and risankizumab (anti-IL-23) have improved outcomes, patient response variability remains unclear. We found four immune-related biological processes enriched in L skin from psoriatic skin and ten immune-related hubs may serve as biomarkers for disease severity as well as for anti-TNFα or anti-IL-23 treatment response."

Biomarker • Dermatology • Immunology • Inflammation • Psoriasis • CCL20 • CXCL10 • CXCL13 • CXCL8 • IL23A • IL6

Reduction of genital psoriasis symptoms in male and female patients treated with risankizumab – interim results from a real-world study (EADV 2025) - "This interim analysis showed a substantial improvement of genital psoriasis symptoms in routine care with risankizumab, particularly in the areas of redness, pain and stinging. There was no evidence of a sex-specific response since both men and women experienced equivalent improvements in GenPsO."

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

Effect of disease duration on effectiveness of biologics in patients with psoriasis: A single-center retrospective study in Japan (EADV 2025) - "Biologic agents included IL-23 inhibitors (risankizumab, guselkumab), IL-17 inhibitors (ixekizumab, secukinumab, brodalumab), and the TNF-α inhibitor (adalimumab). This study suggests that approximately 90% of patients with a disease duration of ≤2 years achieved complete skin clearance within 6M of initiating biologic therapy. In contrast, while comparable percentage of patients with a disease duration >2 years ultimately reached complete clearance skin at 2Y, a longer period was required for some patients to achieve these outcomes."

Retrospective data • Dermatology • Immunology • Psoriasis • IL17A • IL23A

Real-World Effectiveness of Risankizumab Compared to Other Biologics Over 3 Years: Interim Analysis of the VALUE Study (EADV 2025) - P | "In this interim analysis, patients treated with RZB achieved higher durable clinical responses and treatment satisfaction in real-world practice long-term compared to OtherBios, TNFi and IL-17i. VALUE is an ongoing study; not all patients have reached month 37."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Immunology • Psoriasis • IL17A • IL23A • TNFA

Recalcitrant palmoplantar pustulosis successfully controlled with Lebrikizumab (EADV 2025) - "Previous treatments included fumaric acid, PUVA, methotrexate, Tildrakizumab, Risankizumab, Upadacitinib, Guselkumab, Bimekizumab, Ixekizumab, Baricitinib and Apremilast...When we first saw the patient in October 2024, he was receiving Guselkumab and Deucravacitinib, alongside systemic steroids (methylprednisolone, 40 mg/day) and various analgesics, including tramadol, to manage the painful palmoplantar lesions... To the best of our knowledge, this report is the first case of successful treatment of PPP with Lebrikizumab in the literature. It offers clinicians another treatment option for this challenging disease and adds to the literature linking PPP to Th2 inflammation."

Dermatology • Dermatopathology • Immunology • Inflammation • Psoriasis • IL13

"Real-World Efficacy and Safety of Risankizumab in Psoriasis: Insights After Failure of Ustekinumab and Other Biologics" (EADV 2025) - "Of these, 14.71% (5/34) were biologic-naïve, 35.29% (12/34) had previously received ustekinumab, and the remainder had been treated with other biologics such as adalimumab, secukinumab, and ixekizumab. Risankizumab demonstrates a favourable safety and efficacy profile in real-world clinical settings. Its use appears appropriate for both biologic-naïve patients and those with prior biologic therapy failures. No adverse events necessitating treatment discontinuation were observed."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Hepatitis B • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Tuberculosis • IL23A

Risk of infections in psoriasis patients treated with biologic agents and new oral small molecules. Biobadaderm Registry (EADV 2025) - "Materials & Using data from the BIOBADADERM registry, we analyzed crude incidence rates of overall, serious, recurrent, and some special interest infections associated with biologics (etanercept, infliximab, certolizumab, adalimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, risankizumab, tildrakizumab) and oral small molecules (apremilast and dimethyl fumarate). Our study supports the good safety profile of the new systemic drugs in the treatment of psoriasis, especially in terms of the risk of serious infections, with no notable differences between them except for the risk of Candida infections caused by IL-17 inhibitors."

Clinical • Candidiasis • Dermatology • Human Papillomavirus Infection • Immunology • Infectious Disease • Nephrology • Novel Coronavirus Disease • Psoriasis • Respiratory Diseases • IL17A

Real-World Treatment Switch Rates for Risankizumab Compared With Deucravacitinib in Patients With Psoriasis (EADV 2025) - "Switch rate was defined as the proportion of patients who switched to a new targeted immunomodulator (TIM), including biologics, apremilast and deucravacitinib, in the 6- and 12-month follow-up periods after treatment initiation, among patients with ≥6 months and ≥12 months post-index continuous enrolment, respectively. In this real-world setting, patients receiving RZB experienced significantly lower treatment switch rates over 6 and 12 months compared with patients receiving deucravacitinib. These results were consistent after adjusting for differences in baseline characteristics."

Clinical • HEOR • Real-world • Real-world evidence • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Real-World Skin Clearance Target Achievement With Persistent Risankizumab Use in Patients With Moderate-Severe Psoriasis From the CorEvitas Psoriasis Registry (EADV 2025) - "In this real-world analysis, continuous RZB use was highly effective in achieving skin clearance at 6, 12, and 24 months among patients with moderate-severe plaque psoriasis."

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis • IL23A

Real-World Characteristics of Patients Initiating Advanced Therapy for Plaque Psoriasis in the US Specialty Dermatology Networks (EADV 2025) - "Patients ≥18 years of age were indexed at initiation of guselkumab (GUS), risankizumab (RIS), secukinumab (SEC), ixekizumab (IXE), ustekinumab (UST), or deucravacitinib (DEU) for treatment of PsO...Further, DEU initiators were least likely to have prior experience with injectable treatments (4% vs. 14-20%), and were more likely to have previously received treatment with oral apremilast (36% vs 15-22%)... These results provide insights into the demographic and clinical profiles of patients initiating various advanced treatments for PsO in a real-world dermatology setting. GUS initiators exhibited the most severe underlying disease activity as measured by BSA and itch NRS, while DEU initiators had a higher initial burden of comorbidities. These findings highlight the heterogeneous nature of patients initiating advanced therapies for PsO, emphasizing the need for individualized treatment approaches."

Clinical • Metastases • Real-world • Real-world evidence • Dermatology • Immunology • Psoriasis

The risk of reactivation of latent tuberculosis in psoriatic patients treated with IL-23 inhibitors – an observational retrospective single centre study (EADV 2025) - "Materials & We conducted a retrospective, observational study at a single biologic treatment center in Slovakia to assess the rate of TB reactivation in patients with psoriasis treated with IL-23 inhibitors (guselkumab, tildrakizumab, and risankizumab) between April 2019 and April 2025. This study confirms a low risk of TB reactivation in psoriatic patients treated with IL-23 inhibitors. Our findings support the favorable safety profile of IL-23 inhibitors, with no symptomatic or serious cases of active TB observed. Although a slightly higher rate of TB test seroconversion was noted with risankizumab, the difference was not statistically significant."

Retrospective data • Dermatology • Immunology • Infectious Disease • Psoriasis • Respiratory Diseases • Tuberculosis • IL23A

Secondary systemic amyloidosis in a patient with psoriasis and psoriatic arthritis (EADV 2025) - "The patient exhibited refractoriness to multiple therapeutic strategies, including conventional systemic treatments (methotrexate, cyclosporine, sulfasalazine, leflunomide) and various biologics (adalimumab, etanercept, infliximab, certolizumab, golimumab, ustekinumab, guselkumab, risankizumab, ixekizumab, secukinumab). AA amyloidosis is a serious, though rare, systemic complication of chronic inflammatory diseases, particularly rheumatologic disorders such as rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis. It is also increasingly reported in chronic dermatologic conditions like hidradenitis suppurativa and long-standing, uncontrolled psoriasis. Chronic elevation of SAA protein, often linked to suboptimal disease control, leads to amyloid fibril deposition primarily in the kidneys, gastrointestinal tract, liver, and heart, resulting in significant morbidity."

Clinical • Amyloidosis • Ankylosing Spondylitis • Dermatology • Gastrointestinal Disorder • Hematological Disorders • Hidradenitis Suppurativa • Idiopathic Arthritis • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Predictive Factors and Biomarkers for Early PASI100 Response to Biologic Therapies in Psoriasis Patients: A 10-year single-center real-world study (EADV 2025) - "Patients were grouped by the timing of PASI100 achievement (≤16 weeks vs. >16 weeks) and by biologic class: IL-17A (ixekizumab, secukinumab), IL-23 (ustekinumab, risankizumab, guselkumab), and TNF-α inhibitors (etanercept, infliximab, adalimumab, certolizumab). This study highlights the role of clinical and laboratory parameters in predicting treatment response to biologics in psoriasis.** TNF-α inhibitors showed favorable outcomes in terms of drug survival and biomarker reduction. ESR may serve as a useful marker in evaluating delayed treatment response. Identifying these predictors could enhance clinical decision-making and lead to more efficient use of resources in the management of psoriasis."

Biomarker • Clinical • Real-world • Real-world evidence • Dermatology • Dyslipidemia • Immunology • Inflammation • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A • IL23A

Severe Psoriasis in Common Variable Immunodeficiency patients: Guselkumab as a safe and effective option (EADV 2025) - "Systemic therapies including TNF inhibitors were avoided due to potential comorbidities and Ustekinumab was initiated without clinical response after 6 months...Initial treatment with dupilumab, topical PUVA, and corticosteroids showed no response...Due to infection risk TNF inhibitors were avoided, and treatment with Risankizumab (150 mg/12 weeks) plus roflumilast was initiated, with no clinical response despite intensified treatment (150mg/8 weeks)... Severe psoriasis in patients with CVID represents a therapeutic challenge due to comorbidities and infection risk. We present two cases of patients with psoriatic disease effectively treated with GUS, with no increased risk of serious infections. Dose intensification may be required in refractory cases."

Clinical • Chronic Kidney Disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Nephrology • Primary Immunodeficiency • Psoriasis • Psoriatic Arthritis • Pulmonary Disease • Renal Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • IL23A

Safety and Efficacy of Risankizumab in Genital and Scalp Psoriasis in the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16 (EADV 2025) - P4 | "A significantly higher proportion of patients in Study-G with genital PsO achieved the primary endpoint of sPGA-G 0/1 treated with RZB, compared to PBO. Similarly, a significantly higher proportion of patients in Study-S with scalp PsO treated with RZB, compared to PBO, achieved the primary endpoint of scalp IGA 0/1. No new safety signals were identified."

Clinical • P4 data • Dermatology • Immunology • Psoriasis • IL23A

3-year data on effectiveness and quality of life in bio-naïve patients treated with risankizumab or other biologics in clinical practice – German cohort of the VALUE study (EADV 2025) - P | "Bio-naïve patients receiving RZB over the 3-year treatment period showed sustained improvements in effectiveness and QoL. Significant differences could be observed for patients receiving RZB compared to OtherBios after the 3-year observational period. The data indicates that choosing an effective treatment in bio-naïve patients might have favorable long-term treatment outcomes in clinical practice."

Clinical • HEOR • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • IL23A

Subacute Annular Pustular Psoriasis with flexural accentuation: Dramatic response to Risankizumab (EADV 2025) - "IL-23 and IL-17 expression has been reported in pustular psoriasis, and the success of Risankizumab in treating our patient further strengthens the role of IL-23/Th17/IL-17 axis in its pathogenesis. The optimal treatment for APP is still unknown, and this report highlights the safety and efficacy of Risankizumab as an important treatment modality in APP."

Dermatology • Immunology • Psoriasis • Pustular Psoriasis • IL17A • IL23A

Retrospective Evaluation of Biologic Theraphies in HIV-infected Patients with Psoriasis: A Case Series and Review of Literature (EADV 2025) - "Systemic agents such as methotrexate and cyclosporine require cautious use due to their immunosuppressive effects in immunocompromised HIV-positive patients...Additionally, a comprehensive literature search was conducted in the PubMed database for articles published before March 2025 using the search terms: 'HIV' and 'psoriasis' or 'biologic' or 'infliximab' or 'adalimumab' or 'etanercept' or 'ustekinumab' or 'ixekizumab' or 'secukinumab' or 'brodalumab' or 'guselkumab' or 'certolizumab pegol' or 'tildrakizumab' or 'risankizumab' or 'apremilast' or 'bimekizumab.' For patients included in the study, data regarding age, sex, previous treatments, PASI scores, comorbidities, antiviral therapy, viral load, CD4 levels and adverse events were documented... Our study is significant as it provides the most comprehensive literature review to date..."

Retrospective data • Review • Dermatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Psoriasis • CD4 • IL17A

Ultra - Pulsed Fractional CO₂ Laser in the Treatment of Pediatric Nail Psoriasis: A Promising Exploration (EADV 2025) - "Inspired, we treated a pediatric patient with twenty-nail psoriasis using fractional laser plus steroid/tacrolimus ointment to explore a novel approach...Conclusion Pediatric nail psoriasis treatment is challenging due to limited therapies: topical drugs are hindered by poor penetration, intralesional injections cause pain, and adult systemic/biologic agents (e.g., acitretin, risankizumab) lack pediatric data or are costly...Photothermal effects stimulated regeneration, improved nail-bed adhesion, reduced oxidative stress/inflammatory cytokines, and boosted local circulation/immunity. This exploratory approach offers a less painful, well-accepted, and promising topical strategy for pediatric nail psoriasis."

Clinical • Aesthetic Medicine • Dermatology • Hematological Disorders • Immunology • Infectious Disease • Pediatrics • Psoriasis